Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England.

Libby Ellis¹, Charlotte Eversfield², Ewan Gray³, Peter S Hall⁴, Sara Hiom³, David A Jones³, Lennard Yw Lee⁵, Sean McPhail², Katie Spencer², Christopher Halloran⁶

¹GRAIL Bio UK Ltd, London, UK. eellis@grailbio.com.

²National Disease Registration Service, NHS England, London, UK.

³GRAIL Bio UK Ltd, London, UK.

⁴University of Edinburgh, Edinburgh, UK.

⁵University of Oxford, Oxford, UK.

⁶University of Liverpool, Liverpool, UK.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Cancer screening can reduce late-stage diagnoses, expand treatment options, and improve cancer outcomes. We modelled how introducing a multi-cancer early detection (MCED) screening programme in England could impact cancer treatment patterns. METHODS: The proportions of cancers (19 types, diagnosed 2014-2019) treated with resection, radiotherapy, and systemic anti-cancer therapy (SACT)…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.